Prophylactic efficacy of primaquine for preventing Plasmodium falciparum and Plasmodium vivax parasitaemia in travelers: A meta-analysis and systematic review

Travel Medicine and Infectious Disease

Volumn 17, Issue , 2017, Pages 5-18

  Kolifarhood, Goodarz ^a   Raeisi, Ahmad ^b   Ranjbar, Mansour ^c   Haghdoust, Ali Akbar ^d   Schapira, Allan ^e   Hashemi, Saeed ^a,f   Masoumi Asl, Hossein ^g   Mozafar Saadati, Hossein ^a   Azimi, Sara ^a   Khosravi, Nasim ^h   Kondrashin, Anatoly ⁱ  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAHIDOL UNIVERSITY   (Thailand)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e Independent Consultant   (Philippines)

^f SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^h ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁱ I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Chemoprophylaxis; Malaria; Non immune traveler; Primaquine

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CHLOROQUINE PLUS PROGUANIL; DOXYCYCLINE; MEFLOQUINE; PLACEBO; PRIMAQUINE; PROGUANIL; TAFENOQUINE; ANTIMALARIAL AGENT;

ADVERSE OUTCOME; CHEMOPROPHYLAXIS; CONFIDENCE INTERVAL; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HUMAN; INCIDENCE; INFECTION PREVENTION; MALARIA FALCIPARUM; MENTAL DISEASE; META ANALYSIS; PARASITEMIA; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TRAVEL; ANTIBIOTIC PROPHYLAXIS; MALARIA, FALCIPARUM; MALARIA, VIVAX; PARASITOLOGY; PLASMODIUM FALCIPARUM; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ANTIBIOTIC PROPHYLAXIS; ANTIMALARIALS; HUMANS; MALARIA, FALCIPARUM; MALARIA, VIVAX; PARASITEMIA; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIMAQUINE; TRAVEL;

EID: 85020932837     PISSN: 14778939     EISSN: 18730442     Source Type: Journal    
DOI: 10.1016/j.tmaid.2017.04.005     Document Type: Review

References (46)

1. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study. Lancet 380:9859 (2010), 2095–2128.
2. WHO, Global technical strategy for malaria 2016-2030. 2015, World HealthOrganization.
3. WHO, World malaria report 2016., 2016, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/252038/1/9789241511711-eng.pdf?ua=1.
4. WHO, International travel and health: situation as on 1 January 2010. 2010, WHO, Geneva, Switzerland.
5. Tourism highlights, 2009, UNWTO Edition http://www2.unwto.org/facts/eng/highlights.htm.
6. Schwartz, E., Parise, M., Kozarsky, P., Cetron, M., Delayed onset of malaria–implications for chemoprophylaxis in travelers. N Engl J Med 349 (2003), 1510–1516.
7. Fernando, S.D., Rodrigo, C., Rajapakse, S., Chemoprophylaxis in malaria; drugs, evidence of efficacy and costs. Asian Pac J Trop Med 4:4 (2011), 330–336.
8. Greenwood, B., Anti-malarial drugs and the prevention of malaria in the population of malaria endemic areas. Malar J, 9(Suppl 3), 2010, S2.
9. Bradley, D.J., Warhurst, D.C., Guidelines for the prevention of malaria in travellers from the United Kingdom. Commun Dis Rep CDR Rev 7 (1997), R137–R152.
10. The medical letter on drugs and therapeutics. Advice Travel 57:1466 (2015), 52–58.
11. Centers for Disease Control and Prevention, CDC health information for international travel, chapter 3: infectious Diseases related to travel, malaria 2016. 2016, Oxford University Press, New York.
12. Public Health Agency of Canada, Canadian recommendations for the prevention and treatment of malaria. 2014, 135.
13. Schwartz, E., Prophylaxis of malaria. Mediterr J Hematol Infect Dis, 4(1), 2012, e2012045.
14. Chen, L., Wilson, M., Schlagenhauf, P., Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA 297:20 (2007 May 23), 2251–2263.
15. Petersen, E., Malaria chemoprophylaxis: when should we use it and what are the options?. Expert Rev Anti Infect Ther 2:1 (2004 Feb), 119–132.
16. Wallace, M.R., Sharp, T.W., Smoak, B., et al. Malaria among United States troops in Somalia. Am J Med 100 (1996), 49–55.
17. Hill, D., Baird, K., Parise, M., Lewis, L., Ryan, E., Magill, L., Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 75:3 (2006), 402–415.
18. Baird, J.K., Fryauff, D.J., Hoffman, S.L., Primaquine for prevention of malaria in travelers. Clin Infect Dis 37 (2003), 1659–1667.
19. Castelli, F., Odolini, S., Autino, B., Foca, E., Russo, R., Malaria prophylaxis: a comprehensive review. Pharmaceuticals 3 (2010), 3212–3239.
20. Steinhardt, L., Magill, A., Arguin, P., Review: malaria chemoprophylaxis for travelers to Latin America. Am J Trop Med Hyg 85:6 (2011), 1015–1024.
21. White, N., Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis 13 (2013), 175–181.
22. WHO and Global Malaria Programme: Updated WHO Policy Recommendation, Single dose Primaquine as a gametocytocide in Plasmodium falciparum malaria. October 2012 http://www.who.int/malaria/pq_updated_policy_recommendation_en_102012.pdf.
23. Uppsala Monitoring Centre, WHO adverse reaction terminology (WHO-ART). 2001, Uppsala Monitoring Centre, Uppsala.
24. Fryauff, D., Baird, K., Purnomo, Awalludin M., Jones, T., Sublanto, B., et al. Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis. Am J Trop Med Hyg 56:2 (1997), 137–140.
25. Yeom, J., Ryu, S., Oh, S., Choi, D., Song, K., Oh, Y., et al. Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea army. J Korean Med Sci 20 (2005), 707–712.
26. Schwartz, E., Regev-Yochay, G., Primaquine as prophylaxis for malaria for nonimmune travelers: a comparison with mefloquine and doxycycline. Clin Infect Dis 29 (1999), 1502–1506.
27. Weiss, W., 0loo, A., Johnson, A., Koech, D., Hoffman, S., daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 171 (1995), 1569–1575.
28. Fryauff, D., Baird, K., Basri, H., Sumawinata, I., Purnomo, Richie T., et al. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet, 1995, 1190–1193.
29. Nasveld, P., Kitchener, S., Edstein, M., Karl Rieckmann, K., Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel. Trans R Soc Trop Med Hyg 96 (2002), 683–684.
30. Soto J, Toledo J, Rodriquez M, Sanchez J, Herrera R, Padilla J. Primaquine Prophylaxis against Malaria in Nonimmune Colombian Soldiers: Efficacy and Toxicity. A randomized, Double-blind, placebo-controlled Trial.
31. Baird, K., Fryauff, D., Basri, H., Bangs, M., Subianto, B., Wiady, I., et al. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya. Indones Am J Trop Med Hvg 52:6 (1995), 479–484.
32. Baird, K., Lacy, M., Basri, H., Barcus, M., Maguire, J., Bangs, M., et al. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis 33 (2001), 1990–1997.
33. Ling, J., Baird, K., Fryauff, D., Sismadi, P., Bangs, M., Lacy, M., et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of plasmodium falciparum or plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis 35 (2002), 825–833.
34. Croft, A.M., Whitehouse, D.P., Cook, G.C., Beer, M.D., Safety evaluation of the drugs available to prevent malaria. Expert Opin Drug Saf 1:1 (2002), 19–27.
35. Hill, D., Ericsson, C., Pearson, R., Keystone, J., Freedman, D., Kozarsky, P., The practice of travel medicine: guidelines by the infectious Diseases society of America. Clin Infect Dis 43 (2006), 1499–1539.
36. Weber, G., Schwartz, E., Schlaeffer, F., Lang, R., Alkan, M., Imported severe falciparum malaria in Israel. J Travel Med 5:2 (1998 Jun), 97–99.
37. Rahimi, B., Thakkinstian, A., White, N., Sirivichayakul, C., Dondorp, A., Chokejindachai, W., Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. Malar J, 13, 2014, 481, 10.1186/1475-2875-13-481.
38. Tjitra, E., Anstey, N., Sugiarto, P., Warikar, N., Kenangalem, E., Karyana, M., Multidrug-resistant plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med, 5(6), 2008, e128.
39. ArnoldA, Alving A., Hockwald, R., Clayman, C., Dern, R., Beutler, E., et al. The antimalarial action of primaquine against blood stages of falciparum malaria (Panama P-F-6 strain). J Lab Clin Med 46 (1955), 391–397.
40. Collins, W., Jeffery, G., Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg 55 (1996), 243–249.
41. Kondrashin, A., Baranova, A., Ashley, E.A., Recht, J., White, N.J., Sergiev, V.P., Mass primaquine treatment to eliminate vivax malaria: lessons from the past. Malar J, 13, 2014 Feb 7, 51.
42. Tseroni, M., Baka, A., Kapizioni, C., Snounou, G., Tsiodras, S., Charvalakou, M., Prevention of malaria resurgence in Greece through the association of mass drug administration (MDA) to immigrants from malaria-endemic regions and standard control measures. PLoS Negl Trop Dis, 9(11), 2015 Nov 19, e0004215, 10.1371/journal.pntd.0004215 eCollection 2015.
43. Public Health England, Guidelines for malaria prevention in travelers from the United Kingdom. 2016, Crown copyright 2017, 120.
44. Jacquerioz, F.A., Croft, A.M., Drugs for preventing malaria in travellers. Cochrane Database Syst Rev(4), 2009, 10.1002/14651858.CD006491.pub2 Art. No.: CD006491.
45. Bryan, J., Cost considerations of malaria chemoprophylaxis including use of primaquine for primary or terminal chemoprophylaxis. Am J Trop Med Hyg 75:3 (2006), 416–420.
46. Peixoto, H., Brito, M., Romero, G., Monteiro, W., de Lacerda, M., de Oliveira, M., Cost-effectiveness analysis of rapid diagnostic tests for G6PD deficiency in patients with Plasmodium vivax malaria in the Brazilian Amazon. Malar J, 15, 2016, 82.